Trial Profile
A 28-week, Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study With a 24-week Extension Phase Followed by a 52-week Extension Phase to Evaluate the Efficacy and Safety of Simultaneous Administration of Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg Compared to Exenatide Once Weekly 2 mg Alone and Dapagliflozin Once Daily 10 mg Alone in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DURATION-8
- Sponsors AstraZeneca; AstraZeneca AB
- 14 Apr 2021 Results (n=1042) of systematic review and meta-analysis of pooled data from randomized controlled trials (AWARD-10, DURATION-8 and SUSTAIN 9 trials) assessing the safety and efficacy of addition of a glucagon-like peptide-1 receptor agonists (GLP-1RAs) on a Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) compared to SGLT-2i alone in patients with type 2 diabetes mellitus, presented at the Joint Meeting of the European Society of Hypertension and International Society of Hypertension.
- 18 Aug 2020 Results (n=431) assessing efficacy and safety at 104 weeks, published in the Diabetes Care.
- 05 Oct 2018 Results assessing the efficacy and safety of exenatide once weekly across 10 comparator-controlled studies from the DURATION clinical programme (n=2251) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes